Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,358 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 29, 2026, 11:18 AM EDT
Terminated Not applicable Interventional

Peri-Atrial Inflammatory Fat and Atrial Fibrillation

NCT04186169
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Catheter ablation
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 29, 2026, 11:18 AM EDT
No Longer Available No phase listed Expanded access

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

NCT00633373
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 29, 2026, 11:18 AM EDT
Recruiting No phase listed Observational

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain

NCT05342454
View directory record Official record
Conditions
Brain Tumor
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 29, 2026, 11:18 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

NCT03079973
View directory record Official record
Conditions
Nail Psoriasis
Interventions
P-3073 (calcipotriene 0.005%), Vehicle of P-3073
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 29, 2026, 11:18 AM EDT
Recruiting Phase 2 Interventional

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

NCT06665100
View directory record Official record
Conditions
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PUL-042, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
RSLV-132
Biological
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Not applicable Interventional Results available

Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia

NCT02460289
View directory record Official record
Conditions
Male Pattern of Hair Loss, Androgenic Alopecia
Interventions
Treatment: Minoxidil 5% / Botanical Hair Solution for Men
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RRT for PTSD Symptoms in Survivors of Sexual Violence

NCT04073004
View directory record Official record
Conditions
PTSD, Rape Sexual Assault
Interventions
Rapid Resolution Therapy
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Corneal Staining and Physiological Compromise After Eight Hours of Soft Contact Lens Wear

NCT01015768
View directory record Official record
Conditions
Contact Lens-induced Corneal Fluorescein Staining
Interventions
ReNu Multiplus multipurpose disinfecting solution, Control
Device
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 29, 2026, 11:18 AM EDT
Completed No phase listed Observational Results available

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

NCT00823043
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
timolol hemihydrate, timolol maleate
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

NCT03112148
View directory record Official record
Conditions
Healthy
Interventions
10 mg dose MR formulations,10 mg dose of tofacitinib IR solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins

NCT00565604
View directory record Official record
Conditions
Venous Insufficiency
Interventions
Short Catheter Delivery
Device
Lead sponsor
Vascular Solutions LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia

NCT02459158
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
ME1100 inhalation solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Martinez, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus

NCT03193216
View directory record Official record
Conditions
Barretts Esophagus With Dysplasia
Interventions
Alginates
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 29, 2026, 11:18 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

NCT07446101
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Daytona Beach, Florida • Dilworth, Minnesota • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 29, 2026, 11:18 AM EDT
Recruiting Not applicable Interventional

Low Intensity Focused Ultrasound for Chronic Pain: High Resolution Targeting of The Human Insula

NCT06906211
View directory record Official record
Conditions
Chronic Back Pain, Chronic Pain (Back / Neck)
Interventions
low intensity focused ultrasound (LIFU)
Device
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 2 Interventional

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 29, 2026, 11:18 AM EDT
Not listed Phase 3 Interventional

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

NCT06143787
View directory record Official record
Conditions
Bleeding From Teeth, Bleeding Prophylaxis
Interventions
Tranexamic acid
Drug
Lead sponsor
Hyloris Developments
Industry
Eligibility
18 Years to 99 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Loma Linda, California • Stamford, Connecticut • Millcreek, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

NCT03479307
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Phoenix, Arizona • Torrance, California • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 29, 2026, 11:18 AM EDT
Terminated Phase 4 Interventional Results available

Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition

NCT04756427
View directory record Official record
Conditions
CLABSI - Central Line Associated Bloodstream Infection
Interventions
Sodium Citrate 4% Inj Syringe 3Ml
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 11:18 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

NCT00938431
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
14
States / cities
Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 29, 2026, 11:18 AM EDT